FDA panel recommends approval of aclidinium bromide for COPD – ModernMedicine

An FDA advisory panel voted 12-2 to recommend approval of aclidinium bromide (Forest Laboratories and Almirall SA) 400 µg twice daily for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease …

Leave a Reply

Your email address will not be published. Required fields are marked *